Dosing and Administration Protocols

The available literature provides limited specific dosing information for pyrroloquinoline quinone (PQQ) supplementation. Based on the clinical trials identified, most studies appear to have been completed but detailed dosing protocols are not available in the evidence provided.

Clinical Trial Context

Several completed clinical trials have investigated PQQ:

A Phase 3 trial examined a fixed combination of citicoline, homotaurine, and PQQ for glaucoma treatment
Studies have evaluated PQQ combined with hydrogen supplementation in elderly individuals with mild cognitive impairment
Research has investigated PQQ as part of multicomponent antioxidant supplements

Research Dosing

The preclinical studies in the evidence primarily focus on mechanistic research rather than human dosing protocols. Animal studies have examined PQQ's effects on:

Morphine tolerance and dependence modulation
Mitochondrial protection in reproductive cells
Cardiac injury mitigation in diabetes models
General antioxidant and longevity pathways

Evidence Limitations

The current evidence does not provide sufficient detail on specific dosing regimens, administration frequency, or duration of treatment protocols used in human studies. Most clinical trials listed are either withdrawn or completed without published dosing details in the available abstracts.

Important Medical Disclaimer: This information is for educational purposes only and does not constitute personalized medical advice. Dosing and administration of PQQ should only be determined by qualified healthcare providers who can evaluate individual medical history, current medications, and specific health conditions. Consult with a healthcare professional before starting any supplementation regimen.

PQQ

Member access required